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INTRODUCTION 
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INTRODUCTION 
Breast cancer is a heterogeneous disease with wide histological 
appearance. Breast cancer is the most frequent cancer in women worldwide. 
Incidence rate is differs worldwide from 27/100000 females in Eastern 
Africa to 96/100000 females in Europe.
1
 
Breast cancer is the most common cancer among women in India 
according to National cancer registry programme 2011 report.
2
 It is the most 
common non skin cancer in females worldwide. A female has one in eight 
chance of developing breast cancer during her lifetime if she lives up to the 
age of ninety years. By the year 2030 global burden of breast cancer will be 
more than two million every year.
1 
In India the incidence of carcinoma of breast is increasing
1 
and the 
mortality rate for breast cancer in India is 11.1per 10,000.
3
 
Lobule of the breast, part of terminal duct lobular unit, is composed of 
inner secretory epithelial cells and outer myoepithelial cells. 
Immunohistochemistry plays a pivotal role in therapeutic categorization. 
Estrogen receptor (ER) positive and ER negative breast cancers show 
obvious differences in patient characteristics, pathological features, response 
to treatment and prognosis. 
2 
 
Growth of the tumor is directly influenced by the communication 
between tumor cells and stromal cells via the chemical mediators. Loss of 
CD10 in myoepithelial cells and expression in stromal cells of invasive 
ductal carcinoma of breast is associated with poor prognosis.
4 
 
In addition to tumor cells, tumors also contain innate and adaptive 
immune cells, fibroblasts, etc. Recent studies suggest that genetic changes in 
stroma can promote carcinogenesis.
5
 In some condition tumor behavior is 
predicted based on expression of certain genes in stroma. Studies highlights
 
 
the role of stroma in tumor growth, progression and prognosis of breast 
cancer.
6
 
 
 
CD10(common acute lymphoblastic leukemia antigen, CALLA) is a 
cell surface zinc dependant protease. CD10 act as a stem cell regulator in the 
breast and prevents uncontrolled proliferation of stem cells.
7
 It is expressed 
in  breast myoepithelial cells, lymphoid stem cells, neutrophils, and other 
epithelial cells.
8
 CD10 also expressed in stroma of prostate, lung and 
colorectal cancers.
8
 Stromal expression of 
 
    
  
3 
 
  
CD10 is associated with aggressive behavior of epithelial cancers. 
Few studies have indicated that CD10 expression of breast cancer is 
associated with aggressive behavior and poor prognosis.
4,7
 Routine 
chemotherapeutic drugs target the epithelial cells while stromal cells are 
spared which could be responsible for recurrence. It indicates a novel form 
of therapy and stromal cells could be potential therapeutic targets. 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
AIM AND OBJECTIVES 
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AIM OF THE STUDY 
To assess the stromal expression of CD10 in invasive ductal 
carcinoma of  breast NOS type and its correlation with histological grade, 
ER, PR and HER2/ neu expression. 
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OBJECTIVES 
To analyze the expression of CD10 in invasive ductal carcinoma of breast 
NOS type. 
To analyze the correlation of stromal expression of CD10 with ER, PR and  
HER2 neu expression. 
To analyze the correlation of histological grade of carcinoma of  breast  and 
stromal expression of CD10. 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
Breast cancer is the most common non skin cancer in women.
7
 In 
India it is the most common cancer among women according to National 
cancer registry programme 2011 report.
2
 1.67 million new cases were 
diagnosed in 2012 worldwide.
1
 In India 1,45,000 new cases were diagnosed 
in 2012 and about 70,000 deaths were occurred due to breast cancer.
1
 
Mortality rate for breast cancer in India was 11.1 per 100,000
.3
 
Incidence and Epidemiology 
Breast cancer incidence is increased partly due to mammographic 
screening programme. The major benefit of mammographic  screening is the 
detection of in situ carcinoma and number of cases with advanced stage is 
diminished. In India the incidence of breast cancer is increasing and the 
average age of developing a breast cancer is decreasing.
2
 It is more common 
in fourth and fifth decades of life than in the past. 
Breast cancer mortality rate is decreased. It is due to the diagnosis of 
clinically significant cancer at an early stage because of screening and 
effective therapeutic methods. 
     
7 
 
 
Trends in incidence of female breast cancer in selected countries: age-
standardised rate (W) per 100,000 
Ref: GLOBOCAN 2012 v1.O, Cancer Incidence and Mortality Worldwide: 
IARC Cancer Base No.11 
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Trends in mortality of female breast cancer in selected countries: age-
standardised rate (W) per 100,000 
Ref: GLOBOCAN 2012 v1.O, Cancer Incidence and Mortality Worldwide: 
IARC Cancer Base No.1 
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. 
Risk factors 
      Gender is the important risk factor, only one percent carcinoma of breast 
occurs in males. 
Age 
     Breast cancer can occur in any age from childhood to old age. Most of the 
cases occur in the reproductive age groups. Breast cancer is rare below 
twenty five years of age. More than 50% of breast cancer in  young  women 
are either ER negative or HER2/neu positive. Early menarche and late 
menopause increases the risk of breast cancer. Females who has first term 
pregnancy at ages below twenty years have less risk than nulliparous women 
or female over the age of thirty five when they have first birth . It is believed 
that the pregnancy causes terminal differentiation of luminal cells and 
removes the cancer precursor cells. The changes in stroma that occurs in 
pregnancy help the development of invasive breast cancer from in situ 
component.
9 
      
 Family history of     breast   cancer  in   the   first degree relatives 
increase the risk. The risk is due to germline mutation in genes BRCA1, 
located on chromosome 17q21 and BRAC2 located on chromosome 
10 
 
13q12.3. But these genes are responsible only in 16% of familial breast 
cancer.
10,11
 Affected individuals to be closely followed up or can have 
prophylactic mastectomy.
9
 
Epithelial hyperplasia and fibrocystic disease 
           Atypical hyperplasia and fibrocystic disease increases the risk of 
breast cancer. 
Estrogen exposure 
          There is 1.2 to 1.7 fold increased risk associated with hormonal 
replacement therapy with estrogen and progesterone.
12
 Most of the cases are 
ER positive and invasive lobular carcinoma. Oral contraceptive use does not 
affect breast cancer risk. 
Density 
          Increased radio density is a risk factor. It is correlated with young age 
and exposure to hormone. Detection of cancer in the screening  programme  
is difficult.  In some cases MRI may be useful. 
Radiation 
        Exposure to radiation in any form is associated with increased risk for 
breast cancer. 
 
11 
 
Geography 
        Incidence in USA and Europe is 4 to 7 times higher when compared to 
other country.  But number of cases in India is increasing. 
Diet 
        Caffeine consumption may lower the risk and alcohol may increase the 
risk of breast cancer. 
Obesity 
         In obese people the risk is lower below the age of 40 due to low 
progesterone level. In obese postmenopausal women risk is increased due to 
estrogen synthesis in fat. 
Exercise 
       Risk for breast cancer is slightly lower for physically active women. 
Breast feeding 
Increased risk reduction for breast cancer  is noted in women who 
breastfeed longer. Low level of incidence in developing countries may be 
explained by frequent and longer breast feeding.
13
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ETIOLOGY AND PATHOGENESIS 
     Hormones and genetics are the major risk factors for breast cancer. 
Hereditary breast cancer 
     10 to 12% of all breast cancer is due to inheritance of a gene or 
genes.
14
 Multiple affected first degree relatives, breast cancer in younger age 
group, multiple cancer in the family suggest a hereditary etiology. Mutation 
in highly penetrant breast cancer gene is associated with increased risk. 
BRAC1 and BRCA2 accounts for 3% of breast cancer. BRCA1 gene is 
located on chromosome 17q21 is also associated with increased risk for 
ovarian carcinoma. BRCA2 gene is located on chromosome 13q12.3.
15
 
BRAC2 gene is increases the breast cancer risk in men. Germline mutation 
in both the genes is associated with prostatic and pancreatic cancer.  
 
      BRCA1 and BRCA2 are large genes. BRCA1 encodes a protein with 
many function. Functions include recombination DNA repair, cell cycle 
control, chromatin remodeling. 
 
Protein encoded by BRCA2 gene is also involved in DNA repair and 
cytokinesis.
12
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Breast cancer occurring with BRCA1 is usually poorly differentiated, 
have high percentage medullary features and triple negative phenotype or 
overexpression of HER2/neu. These tumors are similar to basal like breast 
cancer. There are some other susceptibility genes which less commonly 
associated with familial breast cancer. Li Fraumani syndrome (germline 
mutation in p53) and Li Fraumani variant syndrome (due to mutation in 
HEK2) together account for about 8% of carcinoma breast. Other syndromes 
with breast cancer include Cowden syndrome (PTEN gene), Peutz Jeghers 
syndrome, familial linitis plastica type c, Louis-Bar syndrome and Faconi 
anemia. 
 
SPORADIC BREAST CANCER 
The major risk factor in this group is related to hormone exposure, 
gender, age at menarche and menopause, reproductive history, breast feeding 
and hormone replacement. Most of the cases occur in postmenopausal 
females and are ER positive. 
 
Hormonal  exposure  causes  growth of target cells, proliferation 
increase the chances of DNA damage. Hormone also stimulate  growth of 
14 
 
premalignant and malignant cells as well as stromal cells which helps in 
tumor development. Estrogen may cause mutation either directly or through 
free radicals in the cells.
16
 
 
Genetic and epigenetic changes in some cells results in recognizable 
breast lesion. Earliest such lesions are proliferative changes. These changes 
include loss of growth inhibiting signals or reduced apoptosis. Hormone 
receptors are increasingly expressed in atypical hyperplasia. At some point 
these changes further acquire additional mutation which results in tumor 
development and neoangiogenesis. According to “cancer stem cell 
hypothesis” cancer occur from stem cell population. The most likely cells are 
ER positive luminal cells. Breast cancers which are ER negative may arise 
from myoepithelial cells which are ER negative. Alternatively an ER 
positive precursor lesion may loss its ER positivity during development of 
cancer.
 
 
Invasion from an in situ cancer occur probably due to an interplay 
between luminal cells, epithelial cells and stromal cells. 
     
  
15 
 
ROLE OF STROMA IN CANCER 
 Microenvironment in the stroma plays a crucial role in neoplastic cell 
proliferation and metastasis.
17,18
 The  interaction between epithelial cells and 
stromal cells is disrupted by many factors produced by neoplastic cells or by 
stromal cells.
19,20 
 
 Matrix metalloproteinase, produced by stromal cells plays a crucial 
role in tumor invasion and metastasis. Studying the role of stromal 
components may help in developing new treatment for neoplastic 
conditions.
21 
 
 CD10 is a zinc dependent metalloproteinase, present on cell surface of 
the stromal cells and are upregulated in the neoplastic cells.
22
 Matrix 
metalloproteinases are involved in the cleavage of proteins of extracellular 
matrix thereby has a key role in remodeling of tissues.
23
 Since CD10 cleaves 
the drug doxorubicin thereby causes chemoresistance. Thus inhibiting the 
activity of CD10 may have an increased response to chemotherapeutic 
agents.
24 
  
  
16 
 
In   the  normal   breast   CD10   mostly  acts  as  a   stem cell 
regulator.
25
 CD10 inhibit signaling proteins which cause differentiation of 
early common progenitor cells in to epithelial and myoepithelial cells.
26,27 
 
Maguer-Satta et al proposed that the transformation of stem cells in 
to neoplastic cells results in altered expression of CD10. A decreased activity 
of CD10 leads to lineage commitment and neoplastic proliferation of cells. 
Thus CD10 loss in myoepithelial cells leads to progression of DCIS in to 
invasive ductal carcinoma of breast.
28 
 
At the same time an increased level of CD10 activity from stromal 
cells leads  to inhibition of epithelial cell differentiation. Thus cancer stem 
cells are maintained. Undifferentiated carcinoma have increased expression 
of CD10.
7 
 
CLASSIFICATION 
More than 95% of breast cancers are adenocarcinomas. They are 
divided into in situ carcinomas and invasive carcinomas.
29
 Neoplastic 
proliferation that is restricted to ducts and lobules is called as in situ 
carcinomas. When  penetration  occurs  to  stroma  through  basement 
membrane it is called as invasive carcinoma. 
17 
 
WHO HISTOLOGICAL CLASSIFICATION OF TUMOURS OF THE 
BREAST 
A) EPITHELIAL TUMORS: 
Invasive ductal carcinoma, Not otherwise specified 
Invasive Lobular carcinoma 
Tubular carcinoma 
Invasive Cribriform carcinoma 
Invasive Papillary carcinoma  
Invasive Micropapillary carcinoma 
Medullary carcinoma 
Mucinous carcinoma 
Apocrine carcinoma 
Metaplastic carcinoma 
   
 
   
18 
 
 
Secretory carcinoma 
Neuro Endocrine carcinoma 
Oncocytic carcinoma 
Adenoid cystic carcinoma 
Acinic cell carcinoma 
Glycogen rich clear cell carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
Micro invasive carcinoma 
Intraductal proliferative lesions 
Usual ductal hyperplasia 
Flat ductal hyperplasia 
Atypical ductal hyperplasia 
 
 
19 
 
 
  Ductal carcinoma in situ 
         Intraductal papillary neoplasm 
Central papilloma  
peripheral papilloma 
Intraductal papillary carcinoma 
Benign epithelial proliferation 
            Adenosis  and its variant 
                  Radial scar or complex sclerosing lesion 
                   Adenomas and its variants 
B) MYOEPITHELIAL LESIONS: 
              Myoepitheliosis 
              Adenomyoepithelial adenosis 
              Adenomyoepithelioma 
    Malignant myoepithelioma 
  
20 
 
C) MESENCHYMAL TUMORS: 
 Hemangioma 
Angiomatosis 
 Hemangiopericytoma 
Myofibroblastoma 
Fibromatosis 
 Inflammatory  myofibroblastoma 
 Lipoma, Leiomyoma 
 Granular cell tumor 
Neurofibroma 
Schwannoma 
 Angiosarcoma, 
 Liposarcoma,  
Rhabdomyosarcoma, 
 Osteosarcoma 
 
21 
 
 Leiomyosarcoma 
 
D) FIBROEPITHELIAL TUMORS: 
           Fibroadenoma 
           Phyllodes tumor 
           Periductal stromal sarcoma 
           Mammary hamartoma 
E) TUMORS OF NIPPLE: 
             Nipple adenoma 
             Paget’s  disease of nipple 
F) MALIGNANT LYMPHOMA: 
             Diffuse Large B cell Lymphoma 
             Burkitt  Lymphoma 
             Extra nodal marginal zone B cell Lymphoma of MALT type 
              Follicular Lymphoma 
  
22 
 
G) METASTATIC TUMORS 
H) TUMORS OF MALE BREAST: 
             Gynaecomastia ,  
 Carcinoma- invasive and in situ 
 
DUCTAL CARCINOMA IN SITU(DCIS) 
Detection of DCIS is increased due to mammography which detects 
calcification and less commonly periductal fibrosis.
30
 It may spread 
throughout duct and lobule. 
Morphological variants of DCIS
31 
 Comedocarcinoma 
 Solid 
 Cribriform 
 Papillary 
 Micropapillary 
 Clinging 
 Cystic hypersecretory 
  
23 
 
Macroscopy 
DCIS may have an ill defined area of fibrous tissue. Soft, pale cheese 
like necrotic debris can be seen on cut surface in comedocarcinoma.
32 
 Most 
of the small lesion are invisible. 
 
Grading 
Using nuclear grade DCIS is divided into three grades
33,34
 
1. High 
2. Intermediate 
3. Low 
High grade 
  This is consists of large pleomorphic cells and high 
nucleocytoplasmic ratio. Nucleus is enlarged, have coarse chromatin and 
large nucleoli. Frequent and atypical mitosis are seen. Comedocarcinoma, 
cribriform or micropapillary are the patterns associated with high grade 
DCIS. 
Low grade 
 This grade will have uniform cells with small regular nuclei.Nucleoli 
is indistinct. Necrosis and mitoses are uncommon. Cribriform, 
24 
 
micropapillary and less commonly solid patterns are the patterns associated 
with low grade DCIS.
 
Intermediate grade 
         Nuclei in this grade show less pleomorphism than high grade 
and they lack uniformity. Necrosis and nucleoli may be seen but they 
are not large.The architectural patterns includes cribriform, solid and 
micropapillary. 
Rare variants 
 Apocrine 
 Neuroendicrine 
 Signet ring cell 
 Cystic hypersecretory 
    Untreated cases of DCIS turn into invasive cancer at a rate of 1% 
per year. Surgical excision followed by radiation is the usual 
treatment. Recurrence rarely occurs due to residual DCIS or occult 
foci of invasion. 
 
 
 
25 
 
LCIS 
Lobular carcinoma in situ(LCIS), otherwise called as lobular 
neoplasia, is usually diagnosed as an incidental finding. It has no 
distinguishing features grossly. Bilateral LCIS is more common than DCIS. 
Lobular  pattern  is  attributed   to   the   loss  of   E  cadherin, a 
transmembrane adhesion molecule, that causes cell to cell cohesion in 
normal breast.  
 
Microscopically LCIS consist of dyscohesive round cells with oval to 
round nuclei and small nucleoli. Signet ring cells are frequently seen.
35
 
Development of Invasion is more common than DCIS. Choices of treatment 
include bilateral prophylactic mastectomy, tamoxifen or clinical follow up 
with mammography. 
 
INVASIVE CARCINOMA 
When stromal invasion is seen it is called as invasive carcinoma, 
whether in situ cancer present or not. If the invasion is less than 0.1cm it is 
called as microinvasion.
36
 Although the carcinoma of breast is develops 
from stem cells, depending upon pattern of differentiation it is divided in to 
two major categories- ductal type and lobular type.
29 
26 
 
 
Clinical features 
Most of the cancers present as a palpable mass, which are associated 
with axillary lymph node involvement in more than 50% cases. Fixation to 
the chest wall and skin dimpling can occur. Tumor involving  the  centre of  
breast  causes   nipple retraction. Blockage of lymphatics produces skin 
thickening and lymphedema. In such cases peau d’ orange appearance occurs 
due to tethering of skin to the breast by cooper ligaments.
37 
 
With the introduction of mammographic screening small sized tumors 
are increasingly detected. They may present as radiodense mass and 
microcalcification 
 
Rarely axillary nodal metastasis or distant metastasis may be the mode 
of presentation of an obscured or occult primary breast cancer. 
 
At molecular level breast cancer is classified based on DNA, RNA, 
and proteins of cancer breast.
38 
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DISTRIBUTION OF HISTOLOGICAL TYPE
39 
CARCINOMA IN SITU     15-30% 
Ductal carcinoma in situ   80% 
Lobular carcinoma in situ  20% 
 
INVASIVE CARCINOMA           70-85% 
No special type    79% 
Lobular carcinoma    10% 
Tubular carcinoma    6% 
Mucinous carcinoma   2% 
Medullary carcinoma   2% 
Papillary carcinoma   1% 
Metaplastic carcinoma   <1% 
 
Invasive carcinoma no special type  
70-80% breast cancers are invasive carcinoma of no special type.
40,41
 
It fails to exhibit histologic characters to classify other specific types such as 
lobular, mucinous or tubular carcinoma. 
28 
 
 
Macroscopic appearance 
Most of the cancers are firm to hard in consistency with irregular 
border. Varied gross appearance can occur. Size of the tumor ranges from 
0.5cm to above 10cm.
42
 Presence of small foci of elastic stroma and 
occasional calcification gives a gritty feeling on cutting the tumor. High 
grade lesions are associated with massive necrosis or calcification. 
 
 
Histological appearance 
Histological appearance is variable. The tumor cells are arranged in 
sheets or cords. Some time they are diffusely infiltrative. Individual cells 
have abundant eosinophilic cytoplasm with pleomorphic nuclei. Glandular 
structure may be extensive or absent. Stromal component varies from 
desmoplastic proliferation to scanty connective tissue. Foci of elastosis and 
necrosis present which may be extensive. Features of special type of breast 
cancer is seen in variable proportion. Occasionally metaplastia, bizarre tumor 
giant cells are seen.
43 
Up to 80% cases associated with DCIS component.   
 
 
29 
 
Molecular subtypes 
There are five major pattern of gene expression in no special type 
group. These are identified with  Gene expression profiling. They luminal A, 
luminal B, normal, basal like and HER2 positive.
44 
 
Luminal A 
It is the largest group and 40-55% of no special type cancer are belong 
to this group. Luminal A type of cancers are ER positive and HER2/neu 
negative. Most of the tumors are well or moderately differentiated and 
mostly occur in post menopausal women. These tumors are slow growing 
and respond well to hormonal therapies.
38 
 
Luminal B 
15-20% of no special type cancer are luminal B type. It is not only 
express ER but also often over express HER2/neu. These tumors are 
generally high grade. Most likely to have nodal spread. These tumors 
respond well to chemotherapy.
38
 
   
 
 
30 
 
Normal breast like 
6-10% cancers are normal breast like type. These are usually ER 
positive, HER2/neu negative well differentiated cancers. Their gene 
expression pattern is similar to normal breast.
38 
 
Basal like 
It accounts for 13-25% of no special type cases. These are 
characterized by ER, PR and HER2/neu negativity. They express markers of 
myoepithelial cells (P- cadherin, keratin, p63) or stem cells (cytokeratin 5 
and 6). Basal like cancers are subgroup of triple negative carcinomas.
45,46
 
Most of the cancer occurring in women with BRCA1 mutation are basal like 
cancers. These are generally high grade and associated with poor prognosis. 
Only 15-20% respond to chemotherapy. 
 
Her2 positive 
It accounts for 7-12% of no special type cancers. This group over 
expresses Her2 protein. They are ER negative cancers. Amplification  of  a  
segment  of   DNA in chromosome 17q21 causes over expression of Her2 
neu.
47
 These tumors are poorly differentiated and frequently have brain  
metastasis. 
31 
 
INVASIVE LOBULAR CARCINOMA 
This occurs commonly in older age group than ductal type. They 
frequently present with larger tumor size, low histological grade and 
hormone receptor positivity. It is the most common special type of breast 
cancer.
48
 Higher rate of multicentricity, bilaterality, subsequent involvement 
of contralateral  breast are frequently seen in invasive  lobular  carcinoma.  
Lobular morphology is due to loss of  E-cadherin and loss of chromosome 
16q.
49,50
 
 
Macroscopy 
Most of the invasive lobular carcinoma forms a mass which is 
indistinguishable from ductal type. Rarely ill defined lesion may occur 
which is difficult to  detect   clinically and with imaging techniques.
51 
 
Histopathology of classic type 
This type accounts for 40% cases.
48
 Small to moderately sized cells, 
arranged in dyscohesive cords, sheets, clusters or single file pattern are the 
hallmark features of this type. Concentric infiltration of tumor cells around 
normal ductular structures gives rise to targetoid appearance. Tumor cells are 
more or less uniform and have round to oval nuclei with inconspicuous 
nucleoli and a thin rim of cytoplasm. Nuclei often eccentrically placed. 
32 
 
Intracytoplasmic lumina is commonly seen.
52
 Mitosis and desmoplasia are 
infrequent. 
 
Other variants 
Alveolar,  
Solid,  
Tubulolobular, 
 Pleomorphic  
Mixed type. 
 
Immunoprofile 
They are commonly positive for ER, PR than in ductal type. HER2 
positivity is lower than ductal type. They also express CEA. 10-16% cases 
express E-cadherin which is an uncommon finding.
53 
 
 
 
33 
 
Metastatic pattern is different in lobular carcinoma and tend to involve 
the peritoneum, retroperioneum, leptomeninges, gastrointestinal tract and 
ovaries.
54 
 
Tubular carcinoma 
It is an uncommon subtype of breast cancer. Accounts for 1-4% if 
invasive breast cancer. Other features include smaller tumor size, low lymph 
node metastasis and lower recurrence. They have favorable prognosis.
55 
 
Macroscopy 
Grossly difficult to differentiate from ductal carcinoma no special 
type. Tumor size ranges from 2mm to 1.5cm. Stellate appearance seen in” 
pure” type. The appearance is diffuse and ill defined in sclerosing type.56 
 
Histopathology 
These tumors composed of predominantly well formed tubules lined  
by  single  layer  of epithelial cells enclosing a lumen. Cells are small to  
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medium in size, cuboidal to columnar in shape and have low grade nuclear 
features. Elastosis is considered as hallmark of tubular carcinoma. Mitosis is 
rare. Stroma is desmoplastic in tubular carcinoma. 90% of the lesion should  
have tubular morphology to be classified as tubular carcinoma.
48
 They  are  
ER and PR positive. 
 
Invasive cribriform carcinoma 
This is an uncommon special type of breast cancer and they have 
excellent prognosis.
57 
 
Macroscopy 
Tumors are firm and may have stellate configuration. Size ranges from 
1 to 3cm.
58 
 
Histopathology 
It shows a sieve like pattern. Tumors consist of round, angulated mass 
and islands of small cells in a desmoplastic stroma. Well defined punched 
out spaces filled with mucin secretion are seen. 90% of the lesion should 
show cribriform morphology.
58 
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MUCINOUS CARCINOMA 
Mucinous carcinomas are uncommon (1 to 4%) tumors. It is more 
common in women over 60 years of age.
48 
 
Macroscopy 
They are well defined, soft tumor and have a glistening gelatinous 
surface on cut section. Tumor size ranges from 1 to 5cm.
59 
 
Histopathology 
Mucinous carcinoma composed of small islands or clusters of 
uniformly round cells in an extensive extracellular mucin background. 
Tumor cells are small with minimal cytoplasm and have dark staining nuclei. 
90% of the tumor mass shows mucinous morphology.
60
 They have good 
prognosis.  
They are ER, PR positive and HER2/neu negative. Mucinous 
carcinoma showing neuroendocrine differentiation are associated with good 
prognosis. 
    
36 
 
 
 
MEDULLARY CARCINOMA 
Medullary carcinoma is usually occurs in the sixth decade of life. It 
has a better prognosis although they have high nuclear grade, aneuploidy and 
absence of hormone receptors expression. There is overexpression of 
adhesion molecules like E-cadherin which limits metastasis. 13% of cancers 
arising in BRCA1 carrier are medullary type.
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Macroscopy 
They are well circumscribed mass, soft in consistency and are 
measuring 1 to 4 cm in diameter.
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Histopathology 
Main criteria includes 
1. Syncitium like sheets of large cells present. Cells have abundant 
cytoplasm with pleomorphic vesicular nuclei and prominent nucleoli. 
This pattern should be present at least 75% of tumor. Glands and 
tubules  are not seen. 
2. Scanty stroma with moderate to severe lymphoplasmacytic infiltrate 
3. Pushing borders.62 
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Invasive papillary carcinoma 
It is a rare breast cancer type and frequently occurs in elderly women.
63 
 
Macroscopy  
Grossly they are well demarcated tumor, soft in consistency and the 
size varies from 1 to 3cm in diameter.
62 
 
Histopathology 
Papillary structure with fibrovascular core is the characteristic feature 
of this tumor. Most of the carcinomas are surrounded by fibrosis and chronic 
inflammatory cells. Cells may have nuclear pleomorphism. Mitosis is 
increased.
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Invasive micropapillary carcinoma 
It is an uncommon type, the epithelial cells form micropapillae with 
out fibrovascular core. It presents as solid tumor and has high lymph node 
metastasis. Tumor cells have moderate pleomorphism and low mitotic 
activity.
65 
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MIXED TYPE 
Mixed ductal and lobular carcinoma 
In this tumor ductal component accounts for 10 to 90% of the tumor.  
Incidence varied from 2 to 6% of all breast tumors.
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Mixed ductal and special type of tumor 
In this tumor, special type of tumor may be tubular, invasive 
cribriform or mucinous. Special type of tumor should form more than 10% 
of tumor mass. 
 
Rare types 
Rare types of breast tumor includes      
1. Secretory carcinoma 
2. Lipid rich, glycogen rich 
3. Apocrine carcinoma 
4. Neuroendocrine carcinoma 
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Secretory carcinoma 
It occurs in all ages. They are well defined and firm neoplasm. They 
are less than 3cm in diameter. Microscopically they have well defined 
border. It is a low grade tumor with solid, microcystic and tubular pattern. 
The characteristic feature is intracellular and extracellular vacuoles which 
may contain mucinous material. Prognosis is excellent in children but in 
adults it is not so good.
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Apocrine carcinoma 
Carcinomas showing cytological and immunological features of 
apocrine cells in more than 90% of tumor are called as apocrine carcinoma. 
They account for less than 1% of the breast tumors. Neoplastic cells have 
abundant, granular, eosinophilic cytoplasm with high grade nuclear features. 
They usually negative for ER, PR but frequently positive for androgen 
receptor and GCDFP-15.
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Neuroendocrine carcinoma 
Primary neuroendocrine tumor of the breast will express 
neuroendocrine markers in more than 50% of the cells.
69
 1 to 4% of the 
tumors are neuroendocrine tumors. Histologically they include solid, small 
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cell and large cell neuroendocrine tumors. Solid type will have nest and 
trabeculae separated by thin fibrvascular stroma. They may have rosette like 
structure and peripheral palisadding. They tend to have poor prognosis than 
conventional invasive ductal carcinoma breast.
70
  
 
Metaplastic carcinoma 
These are heterogeneous group of tumors contain features of 
malignant epithelial elements and mesenchymal elements. Squamous and/or 
spindle cell components are present. Mesenchymal elements includes 
cartilage, bone and myxoid stroma. These tumors are uncommon.
71
 Grossly 
they form large, firm, well defined tumor measuring up to 5cm in diameter. 
Microscopically two major subtypes include monophasic and biphasic. 
Conventional invasive carcinoma no special type present in biphasic form.
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These tumors are triple negative and express cytokeratin 5/6, cytokeratin 14, 
cytokeratin 7 and CAM5.2. 
Investigation 
1. Mammography 
2. cytology 
3. Needle core biopsy 
4. Open biopsy and frozen section 
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1. Mammography 
Mammography helps in detecting small tumors of size 1mm to 2mm. 
Mammography  detects calcified lesions. Cancer breast is associated with 
50%to 60% of calcifications. 
2. cytology 
 All palpable breast lesions are initially investigated with fine needle 
aspiration cytology. Although it is a cost effective, simple method but 
invasion can not be detected. 
Role of FNAC in cancer breast 
The   confiramation of  clinically suspected  and inoperable cancer. 
To investigate the suspected recurrence or metastasis in case of 
previously diagnosed cancer. 
To obtain tumor cells for special analysis such as IHC and cytogenetic 
analysis. 
3. Needle core biopsy 
 Needle core biopsy is useful in diagnosing cancer breast with invasive 
component. Hormonal status(ER,PR) and HER2 overexpression can be 
studied. 
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4. Open biopsy and frozen section 
 There are two types of biopsy one is excision biopsy and the other one 
is incisional biopsy. 
 Frozen sections are used to evaluate margin and to confirm the 
diagnosis of suspected invasive cancer detected by other methods. 
Disadvantages of frozen section 
 Sampling error 
 Technical error 
 Histological misinterpretation 
Staging  
TNM system of staging is commonly used and it is adopted by 
American joint committee on cancer(AJCC). 
 
Grading 
Nottingham modification of the Bloom-Richardson system of grading 
is commonly used. It is based on microscopic assessment of tubule 
formation, nuclear pleomorphism and mitotic count.
73 
43 
 
 
Prognostic and predictive factors 
Prognosis of breast cancer varies widely. Prognosis mainly determined 
by pathological examination of primary cancer and axillary  node. It is useful 
for patient counseling, appropriate treatment and clinical trials.
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Invasive versus in situ carcinoma 
Most of the in situ carcinoma can be cured with adequate where as 
more than 50% patients with invasive cancer have metastasis.
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Distant metastasis 
Distant metastasis is a poor prognostic factor. But it depends up on 
other factors like tumor type and location metastasis.
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Lymph node metastasis 
In the absence of distant metastasis axillary nodal involvement is the 
important factor. Metastatic foci of less than 0.2cm are called as 
micrometastasis. Macrometastasis are more than 0.2cm in size and are 
important prognostic factor. Nearly 10% - 20% of women without axillary 
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node metastasis may have recurrence due to metastasis via blood or internal 
mammary node.
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Tumor size 
Size of the tumor is second most important prognostic indicator. 
Number of axillary nodal metastasis is increases with the size of the tumor.
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Locally advanced disease 
Cancer involving chest wall and skin are difficult to treat. They are 
associated with poor prognosis. 
 
Inflammatory carcinoma 
Carcinoma breast presenting with swelling and skin involvement have 
poor prognosis. 
 
Histologic subtype 
When compared to carcinoma of breast no special type women with 
special type of invasive cancer (tubular, medullary, mucinous, lobular) have 
increased survival rate. 
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Histologic grade 
The Nottingham Histologic Score is the commonly used grading 
system. It combines nuclear grade, mitotic rate and tubule formation to 
classify carcinoma of breast as Grade I, II and III carcinoma.
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Estrogen and progesterone receptors 
Patients with ER and PR positive breast cancer have increased disease 
free survival rate. ER and PR positivity is positively correlated with response 
to hormonal therapy.
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HER2/neu 
Response to trastuzumab is predicted with overexpression of 
HER2/neu oncogene. Women with tumor which showing overexpression 
will have poor prognosis. Her2/neu overexpression is correlated with high 
grade tumor.
78 
Stromal CD10 expression 
Stromal expression of CD10 is associated with hormonal receptor 
(ER) negativity, high grade tumor and low survival rate.
4,7 
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Types of margin 
Better prognosis has been observed in tumors with pushing type of 
margin. This applies to medullary carcinoma as well as other well 
circumscribed tumors. 
Micro vessel density 
Invasive breast carcinoma will behave in aggressive manner when 
they have increased vascularity in the surrounding stroma. 
 
Elastosis 
Tumors with no elastosis will have reduced response to hormonal 
therapy. 
 
TREATMENT 
Type and extent of  the breast cancer determines the treatment . 
1) Surgery    
2) Radiation therapy    
3) Hormonal therapy   
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         4) Chemotherapy   
                    5) Target therapy 
 
Simple mastectomy, radical mastectomy and modified radical 
mastectomy are the some of the surgical methods. Radiation therapy is  used  
in  postoperatively  and   to   control  the  local  recurrence of  carcinoma. 
The chemotherapy is given as an neoadjuvant therapy and after local 
treatment and also given in breast cancers with axillary node metastasis. 
Chemotherapy can be used in combination with surgery and radiation in 
patients with large (>3 cm) tumors in order to avoid mastectomy. The 
hormonal therapy is used in   hormone receptor-positive breast carcinomas. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
MATERIALS & METHODS 
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MATERIALS AND METHODS 
STUDY DESIGN: 
The present study is a Prospective study conducted in the Department 
of Pathology during the period from July 2014 to June 2015. Ethical 
clearance for the study was obtained from the Ethics Committee of  
Coimbatore  Medical  College, Coimbatore. 
A total sample of 30 cases of invasive ductal carcinoma breast NOS 
type were analyzed. 
PLACE OF STUDY: 
Department of  Pathology, Coimbatore  Medical  College, Coimbatore 
STUDY PERIOD: 
 July 2014 – June 2015 
INCLUSION CRITERIA: 
Invasive    ductal  carcinoma  of   breast   not  otherwise specified 
type.   
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EXCLUSION CRITERIA: 
1. Patients on chemotherapy and radiotherapy 
2. Male patients 
3. Ill fixed specimen 
The study was done in 30 invasive ductal carcinoma of breast cases sent 
from Department of Surgery and Department of Surgical Oncology, 
Coimbatore Medical College Hospital, Coimbatore for histopathological 
examination .  
Hematoxylin and Eosin stained microscopic slides of the primary tumor 
were reviewed to confirm the diagnosis, to define tumor subtype and to 
standardize grading of invasive ductal carcinoma according to the 
Nottingham Modification of the Bloom and Richardson system. 
GRADE SCORE 
I 3T0 5 
II 6&7 
III 8&9 
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Microscopic grading of carcinoma of breast: 
Nottingham Modification of the Bloom and Richardson system 
Tubule formation 
1 point: Tubular formations in >75% of the tumor 
2 point: Tubular formations in 10-75% of the tumor 
3 point: Tubular formations in <10% of the tumor 
Nuclear pleomorphism 
1 point: Nuclei with minimal variation in size and shape 
2 point: Nuclei with moderate  variation in size and shape 
3 point: Nuclei with marked  variation in size and shape 
Mitotic count 
1 point: upto 11/10 hpf, 2 point: 12 to 23/10 hpf, 3 point: 23 or more/ 
10 hpf 
 
 
Allred/ Quick Score system
82 
Score Score for proportion Score for intensity 
0 No staining No staining 
1 <1% Nuclei staining Weak staining 
2  1%-10% Nuclei staining  Moderate staining 
3 11%-33% Nuclei staining Strong staining 
4 34%-66% Nuclei staining  
5  67%-100% Nuclei staining   
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ER and PR markers were considered positive when the combined 
score for proportion and intensity is 3 or more. 
 
 HER 2-neu scoring was done as per following table
83 
Staining pattern Score HER2 neu 
Overexpression 
No staining or membrane 
staining<10% tumor cells 
0 Negative 
Faint/perceptible membrane 
staining in >10% cells 
1+ Negative 
Weak to moderate complete 
membrane staining in >10% 
cells 
2+ Weak 
Strong complete membrane 
staining in >30% cells 
3+ Strong 
 
     
CD10 scoring was done as per the following table
79
. Pattern of 
staining for CD10 is cytoplasmic and membranous positivity in 
stromal cells. Both negative and weak expression were considered as 
52 
 
negative. Only strong CD10 expression was considered as positive for 
statistical purpose. 
 
 
 
Formalin fixed and paraffin embedded tissue specimen of invasive 
breast carcinoma were examined. Four micron sections were cut and stained 
for immunohistochemistry with mouse monoclonal antibodies.
79
 The 
staining was done as per the following protocol.  
     
 
  
Score Result CD10 staining 
0 Negative <10% stromal positive cells 
(cytoplasmic and membrane 
positivity) 
1 Weak 10%-30%  stromal positive cells 
2 Strong >30% stromal positive cells 
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REAGENTS  USED  IN  IMMUNOHISTOCHEMISTRY 
1.Peroxide block 
2. Power block 
3. Chromogen  - Diaminobenzidine 
4. Liquid DAB substrate 
5. Super enhancer 
6. Poly HRP reagent  
7. Hematoxylin- counter stain 
8. Buffer solutions 
 
BUFFERS USED 
1. TRIS  EDTA : pH- 9.0 
TRIS buffer salt : 6.05 gm 
Disodium EDTA: 0.744 gm 
Distilled water :   1000ml 
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2. TRIS BUFFER pH - 8 
TRIS buffer salt : 6.05 gm 
Sodium chloride : 8 gm 
Distilled water :   1000ml 
1N Hydrochloric acid : 3 ml 
3. CITRATE BUFFER  pH-6 
Trisodium citrate : 2.94 gm 
        Distilled water :   1000ml 
1N Hydrochloric acid : 5 ml 
 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1. Overnight incupation of slides in incubator at 600C 
2. Deparaffinisation of the tissue sections in xylene for 30 minutes 
3. Wash with absolute alcohol for five minutes with two changes 
4. Tap water wash for ten minutes     
5. Rinse in distilled water for five minutes 
6. Antigen retrieval was done by placing the slides in microwave 
with appropriate buffers for 20 minutes. 
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7. Cool in room temperature, then rinse in distilled water. 
8. Wash in TBS buffer for five minutes with two changes. 
9. Apply peroxide block for ten minutes. 
10.  Wash in TBS buffer for five minutes with two changes 
11. Apply power block on sections for ten minutes. 
12. Drain the slide, add primary antibody and incupation at Room 
temperature in moisture chamber for 1 hour. 
13. Wash in TBS buffer for five minutes with two changes. 
14. Cover the slides with superenhancer for thirty minutes 
15. Wash in TBS buffer for five minutes with two changes 
16. Then apply reagent of poly HRP for thirty minutes. 
17. Wash in TBS buffer for five minutes with two changes. 
18. Apply DAB chromogen for five to eight minutes. 
19. Wash in TBS buffer for five minutes with two changes. 
20. Tap water wash for five minutes. 
21. Counterstain with Mayers hematoxylin for one minute. 
22.      Tap water wash for five minutes. 
23. Air dry and mount in DPX. 
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Statistical analysis: 
 The collected data was tabulated and analyzed. Continuous data was 
expressed as mean. Statistical correlation between stromal expression of 
CD10 and histopathological grade, ER, PR and HER2/neu expression were 
performed as per Chi square test. p values of less than 0.05 were considered 
as significant. Pearson coefficient of correlation was used to assess the 
relationship between the variables. 
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OBSERVATION AND RESULTS 
Table 1: Distribution of IDC of breast according to different age group 
AGE NUMBER % 
21-30 1 3.3% 
31-40 6 20% 
41-50 11 36.7% 
51-60 9 30% 
>60 3 10% 
TOTAL 30 100% 
 
Total of 30 cases were studied and the following observations were obtained. 
The age of the patients ranges from 23 to 72 years with mean age of  48 
years. 
 
Majority of  IDC of breast cases belong to 41- 50 age group(36.7%). 
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CHART 1: DISTRIBUTION OF IDC OF BREAST ACCORDING TO 
DIFFERENT AGE GROUP 
 
 
Majority of  IDC of breast cases belong to 41- 50 age group(37%). 
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Age Distribution(N=30)
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MEAN AGE OF GROUP 
 
AGE MEAN SD 95% CI OF MEAN Lowest age Highest 
age LOWER UPPER 
TOTAL 48.1 yrs 10.5 yr 44 yrs 52 yrs 23 yrs 72 yrs 
 
Mean age of the study group is 48.1years 
Lowest age in this study is 23 years. 
Highest age in this study is 72 years. 
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TABLE  2: STROMAL EXPRESSION OF CD1O IN  
BREAST CARCINOMA 
STROMAL  CD10 EXPRESSION 
NEGATIVE WEAK 
POSITIVE 
STRONG 
POSITIVE 
TOTAL 
8(27%) 8(27%) 14(46%) 30 
 
CHART 2: STROMAL EXPRESSION OF CD1O IN  
BREAST CARCINOMA 
 
 
73% (22 out of 30) of the cases showed positivity for CD10 in the 
stroma, of which 46%(14) cases were strongly positive and 27%(8) 
were weakly positive. 
 
Negative(8)
27%
Weak positive(8)
27%
Strong 
positive(14)
46%
CD10 expression
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TABLE 3: STROMAL CD10 EXPRESSION WITH 
HISTOPATHOLOGICAL GRADE 
 CD10 
GRADE NEGATIVE WEAK 
POSITIVE 
STRONG 
POSITIVE 
TOTAL 
I 2 3 3 8 
II 4 4 1 9 
III 2 1 10 13 
TOTAL 8 8 14 30 
 
77% (10 out of 13) of the grade III Invasive ductal carcinoma of breast 
showed strong stromal CD10 expression. The association is  statistically 
significant,   p value is less than 0.05 (p value 0.04, Chi -square test). 
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CHART 3: ASSOCIATION OF STROMAL CD10 EXPRESSION 
WITH HISTOPATHOLOGICAL GRADE 
 
 
77%( 10 out of 13) of the grade III Invasive ductal carcinoma of breast 
showed strong stromal CD10 expression. The association is  statistically 
significant,   p value is less than 0.05. 
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NEGATIVE(n=8) WEAK POSITIVE(n=8) STRONG 
POSITIVE(n=14)
CD10
GRADE I 25% 38% 38%
GRADE II 44% 44% 11%
GRADE III 8% 15% 77%
Association of CD10 with Grade [N=30][p>0.05]
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TABLE 4: ASSOCIATION OF STROMAL CD10 
EXPRESSION  WITH ER 
 CD10 
ER NEGATIVE WEAK 
POSITIVE 
STRONG 
POSITIVE 
TOTAL 
NEGATIVE 2 3 13 18 
POSITIVE 6 5 1 12 
TOTAL 8 8 14 30 
 
92% (13 /14) of the strong stromal CD10 positive  Invasive ductal carcinoma 
of  breast showed  ER negativity . The association is  statistically significant,   
p value is less than 0.05(p value 0.002, Chi- square test).  
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CHART 4: ASSOCIATION OF STROMAL CD10  
EXPRESSION  WITH ER 
 
 
92% (13 /14) of the strong stromal CD10 positive  Invasive ductal carcinoma 
of  breast showed  ER negativity . The association is  statistically significant,   
p value is less than 0.05(p value 0.002, Chi- square test).  
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ER - POSITIVE 75% 62% 8%
Association of CD10 with ER[N=30][p<0.05]
65 
 
TABLE 5: ASSOCIATION OF STROMAL CD10  
EXPRESSION  WITH PR 
 CD10 
PR NEGATIVE WEAK 
POSITIVE 
STRONG 
POSITIVE 
TOTAL 
NEGATIVE 3 1 13 17 
POSITIVE 5 7 1 13 
TOTAL 8 8 14 30 
 
92% (13 /14) of the strong stromal CD10 positive  Invasive ductal carcinoma 
of  breast showed  PR negativity . The association is  statistically significant,   
p value is less than 0.05 (p value 0.0005, Chi- square test). 
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CHART 5:  ASSOCIATION OF STROMAL CD10  
EXPRESSION  WITH PR 
 
 
92% (13 /14) of the strong stromal CD10 positive  Invasive ductal carcinoma 
of  breast showed  PR negativity . The association is  statistically significant,   
p value is less than 0.05 (p value 0.0005, Chi- square test). 
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TABLE 6: ASSOCIATION OF  STROMAL CD10 EXPRESSION 
WITH HER2/NEU 
 CD10 
HER2/neu NEGATIVE WEAK 
POSITIVE 
STRONG 
POSITIVE 
TOTAL 
NEGATIVE 8 7 4 19 
POSITIVE 0 1 10 11 
TOTAL 8 8 14 30 
 
71% (10/14) of the stromal CD10 positive  Invasive ductal carcinoma of  
breast showed HER2/neu expression. The association is statistically  
significant,   p value is less than 0.05 (p value 0.0009, Chi- square test). 
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CHART 6: ASSOCIATION OF  STROMAL CD10 EXPRESSION 
WITH HER2/NEU 
 
 
 
71% (10/14) of the stromal CD10 positive  Invasive ductal carcinoma of  
breast showed HER2/neu expression. The association is statistically  
significant,   p value is less than 0.05 (p value 0.0009, Chi- square test). 
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TABLE 7: ASSOCIATION OF CD10 WITH HISTOLOGICAL 
GRADE AND ER 
HISTOLOGICAL GRADE VS ER WITH CD10 
GRADE CD10 Total 
NEGATIVE WEAK 
POSITIVE 
STRONG 
POSITIVE 
GRADE I ER NEGATIVE 0 1 2 3 
POSITIVE 2 2 1 5 
GRADE II ER NEGATIVE 2 1 1 4 
POSITIVE 2 3 0 5 
GRADE III ER NEGATIVE 0 1 (77%)10 11 
POSITIVE 2 0 0 2 
 
77% of  stromal CD10 positive cases associated with histological grade III 
and ER negativity. Increased stromal CD10 expression is associated with 
higher tumor grade  and  reduced  ER expression . 
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CHART 7: ASSOCIATION OF CD10 WITH HISTOLOGICAL 
GRADE AND ER 
 
 
77% of  stromal CD10 positive cases associated with histological grade III 
and ER negativity. Increased stromal CD10 expression is associated with 
higher tumor grade  and  reduced  ER expression . 
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ER ER ER
GRADE I GRADE II GRADE III
CD10 NEGATIVE 0% 25% 22% 22% 0% 15%
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CD10 STRONG POSITIVE 25% 13% 11% 0% 77% 0%
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TABLE 8: ASSOCIATION OF CD10 WITH HISTOLOGICAL 
GRADE AND PR 
 
HISTOLOGICAL GRADE VS PR WITH CD10 
GRADE CD10 Total 
NEGATIVE WEAK 
POSITIVE 
STRONG 
POSITIVE 
GRADE I PR NEGATIVE 2 0 2 4 
POSITIVE 0 3 1 4 
GRADE II PR NEGATIVE 1 1 1 3 
POSITIVE 2 4 0 6 
GRADE III PR NEGATIVE 0 0 (77%)10 10 
POSITIVE 2 1 0 3 
 
77% of  stromal CD10 positive cases associated with histological grade III 
and PR negativity. Increased stromal CD10 expression is associated with 
higher tumor grade  and  reduced  PR expression . 
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CHART 8: ASSOCIATION OF CD10 WITH HISTOLOGICAL 
GRADE AND PR 
 
 
77%  of  stromal CD10 positive cases associated with histological grade III 
and PR negativity. Increased stromal CD10 expression is associated with 
higher tumor grade  and  reduced  PR expression . 
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TABLE 9: ASSOCIATION OF CD10 WITH HISTOLOGICAL 
GRADE AND HER2 
 
HISTOLOGICAL GRADE VS HER2  WITH CD10 
GRADE CD10 Total 
NEGATIVE WEAK 
POSITIVE 
STRONG 
POSITIVE 
GRADE I HER
2 
NEGATIVE 2 2 0 4 
POSITIVE 0 1 3 4 
GRADE II HER
2 
NEGATIVE 4 4 1 9 
POSITIVE 0 0 0 0 
GRADE III HER
2 
NEGATIVE 2 0 4 6 
POSITIVE 0 1 (46%)6 7 
 
46%  of  stromal CD10 positive cases associated with histological grade III 
and HER2/neu positivity. Increased stromal CD10 expression is associated 
with higher tumor grade  and  increased HER2  expression . 
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CHART 9: ASSOCIATION OF CD10 WITH HISTOLOGICAL 
GRADE AND HER2/NEU 
 
 
46%  of  stromal CD10 positive cases associated with histological grade III 
and HER2/neu positivity. Increased stromal CD10 expression is associated 
with higher tumor grade  and  increased HER2  expression . 
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 IMMUNOHISTOCHEMISTRY OF STROMAL CD 10 
 
 
 
 
 
 
 
 
 
 
 
          Picture of stromal CD10 cytoplasmic positivity 1+(10%-30%  stromal  
positive cells) 
 
 
 
 
 
 
 
 
  
 
    Picture of stromal CD10 Cytoplasmic positivity 2+(>30% stromal  
positive cells) 
            COLOR PLATE 2 
   
 IMMUNOHISTOCHEMISTRY OF CD 10 
 
 
 
 
 
 
 
 
 
Picture of stromal CD10 negativity,but myoepithelial cells positive  
for  CD10 
 
 
 
 
 
 
 
 
 
  
            Picture of  stromal CD10 negativity  
  
             COLOR PLATE 3 
IMMUNOHISTOCHEMISTRY OF ER 
 
 
 
 
 
 
 
 
 
   
Picture showing ER negativity  
 
 
 
 
 
 
 
 
 
 
       Picture showing ER nuclear positivity(5/8) 
  
 
     COLOR PLATE 4 
IMMUNOHISTOCHEMISTRY OF PR 
 
 
 
 
 
 
 
 
 
  
Picture showing PR negativity 
 
 
 
 
 
 
 
 
 
 
Picture showing PR nuclear positivity (5/8) 
  
COLOR PLATE 5 
IMMUNOHISTOCHEMISTRY OF HER2/neu 
 
 
 
 
 
 
 
 
 
 
Picture showing HER2/neu Weak to moderate complete membrane 
staining positivity(2+) 
 
 
 
 
 
 
 
 
 
 
 Picture showing HER2/neu Strong complete membrane staining in   
>30% cells positivity(3+) 
  
COLOR PLATE 6 
HEMATOXYLIN &EOSIN STAINING OF IDC BREAST 
 
 
 
 
 
 
 
 
 
   
Invasive carcinoma of no special type. Tubules lined 
by carcinoma cells .(10X) 
 
 
 
 
 
 
 
 
 
 
Invasive carcinoma of no special type. Cords of neoplastic 
cells invading into the stroma.(10X) 
 
  
COLOR PLATE 7 
HEMATOXYLIN &EOSIN STAINING OF IDC BREAST 
 
 
 
 
 
 
 
 
 
Invasive carcinoma of no special type. Sheets 
of closely packed pleomorphic cells with mitosis(40X) 
  
 
 
 
 
 
 
 
 
 
 
Invasive carcinoma of no special type. Sheets of  closely 
 packed carcinoma cells(10X) 
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DISCUSSION 
Invasive ductal carcinoma of breast is the third most frequent 
carcinoma reported in the Department of Pathology, Coimbatore Medical 
College and  is accounting for 10.3% of total malignancies in the year 2014. 
In the present study majority of invasive ductal carcinoma of breast 
cases belong to ages between 41 and 50 years. 
The mean age of invasive ductal carcinoma of breast in this study was 
48 years.  Puri et al found  48.5 years  as mean age of patients in their 
study.
79 
In this study 73% (22 out of 30) of the cases showed positivity for 
CD10 in the stroma, of which 46%(14) cases were strongly positive and 
27%(8) were weakly positive. In a study done by Makretsov et al 79%(205 
out of 258) of invasive ductal carcinoma of breast showed  stromal CD10 
expression.
4
 Puri  et al also found CD10 expression in 80%(40/50) of 
invasive ductal carcinoma of breast.
79
 Study done by Thomas S et al shows 
stromal CD10 positivity  in 55% (16out of 29)  of cases.
81 
In the present study Stromal CD10 positivity was found in 77% cases 
of grade III invasive ductal carcinoma of breast. Association of CD10 
expression with grade III invasive ductal carcinoma of breast is  statistically 
significant with p value <0.05(0.04). Jana SH et al study shows stromal 
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CD10 positivity in 65% cases of grade III invasive ductal carcinoma of 
breast and the association is statistically significant.
7
 Makretsov et al study 
shows  59%  positivity for stromal CD10 in grade III cases.
4
  
TABLE 10: COMPARISON BETWEEN PRESENT STUDY AND 
OTHER STUDIES 
S.No Name of the 
Study 
Sample 
size 
Direct 
correlation 
Inverse 
correlation 
No 
correlation 
1. Present 
study 
30 Higher grade, 
HER2/neu 
positive 
ER, 
PR 
Age 
2. Thomas et 
al(2013)
81 
29 HER2, 
Chemotherapy 
ER  
3. Makretsov 
NA et al 
(2007)
4 
453 Higher grade, 
Decreased 
survival 
ER PR, 
HER2 
4. Iwaya K et 
al (2002)
80 
123 Lymph node 
metastasis 
 Age, 
Histological 
grade 
5. Jana SH et 
al (2014)
7 
70 Higher grade, 
HER2, 
Poor prognosis 
ER PR, 
Age, 
Lymphnode 
status 
6. Puri et 
al(2011)
79 
50 Higher grade, 
HER2, 
Ki67 
ER, 
PR 
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In the present study inverse correlation between stromal CD10 
expression and hormonal receptors expression was observed. 
92%(13/14 cases) of the stromal CD10 positive cases of invasive 
ductal carcinoma of breast not expressed both ER and PR. This inverse 
correlation was found to be statistically significant with the  p value less than 
0.05(0.002 for ER and 0.0005 for PR). Puri et al found correlation between 
stromal CD10 expression and hormonal receptors negativity. But their 
results are statistically not significant.
79
 Makretsov et al study shows 
statistically significant correlation between stromal CD10 expression and ER 
negativity.
4
 Jana SH et al study shows no correlation between stromal CD10 
expression  and  PR.
7
 
In the present study we obtained direct correlation between stromal 
CD10 expression and HER2/neu over expression. 71% (10/14 cases) of 
stromal CD10 positive invasive ductal carcinoma of  breast cases showed 
HER2/neu positive. This correlation is statistically significant with the p 
value less than 0.05(p value 0.0009).  Jana SH et al study also shows 
correlation between stromal CD10 expression and  
HER2/neu over expression.
7
 Puri et al study shows statistically 
significant correlation between stromal CD10 expression and HER2/neu 
over expression.
79
 Makretsov et al does not find statistically significant 
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correlation between stromal CD10 expression and HER2/neu over 
expression.
4
 
 
CD10 can be a therapeutic target for managing carcinoma breast since 
it cleaves the chemotherapeutic agent doxorubicin and results in resistance   
to   chemotherapy.   CPI0004Na   is  a   CD10  cleavable peptide prodrug of 
doxorubicin. Experimental studies show CPI0004Na  improves antitumor 
efficacy and reduces the toxicities of chemotherapeutic agents.
81 
 
Thus documenting the stromal CD10 status in carcinoma breast cases 
before and after chemotherapy is important as a possible prognostic and 
predictive factor. 
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SUMMARY 
 
A study conducted at Coimbatore Medical College, Coimbatore 
during the year 2014-2015. The study titled as “TO ASSESS THE 
STROMAL EXPRESSION OF CD10 IN INVASIVE DUCTAL 
CARCINOMA OF BREAST AND ITS CORRELATION WITH 
HISTOLOGICAL GRADE, ER, PR AND HER2 NEU EXPRESSION ”. 
The study consists of 30 cases of invasive ductal carcinoma of  breast  NOS 
type. In all the cases immunohistochemistry was done with markers ER, PR, 
HER2/neu and CD10.  
 
Grading of invasive ductal carcinoma was done according to the 
Nottingham Modification of the Bloom and Richardson system. 
 
Patients who had underwent preoperative  neo adjuvant chemotherapy  
and radiotherapy was excluded. Statistical analysis was done, results were  
compared  with various  available  previous studies. 
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This study showed 
1. Majority of invasive ductal carcinoma of breast cases belong to 
ages between 41 and 50 years. 
 
2. The mean age of invasive ductal carcinoma of breast in this study 
was 48 years. 
3.  73% (22 out of 30) of the cases showed positivity for CD10 in the 
stroma, of which 46%(14) cases were strongly positive and 27%(8) 
were weakly positive. 
 
4. Stromal CD10 positivity was found in 77% cases of grade III 
invasive ductal carcinoma of breast. Association of CD10 
expression with grade III invasive ductal carcinoma of breast is 
statistically significant. p value is < 0.05 (p value 0.04, Chi -square 
test). 
 
5. Inverse correlation was found between stromal CD10 expression 
and estrogen  receptor  expression, p value was < 0.05. As the 
stromal expression CD10 increases, ER positivity  decreases. 
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6. Inverse correlation was found between stromal CD10 expression 
and progestrone  receptor  expression, p value was < 0.05. As the 
stromal expression CD10 increases, PR positivity  decreases. 
 
7. Direct correlation was found between stromal CD10 expression  
and HER2/neu over expression, p value is < 0.05. As the positivity 
of HER2  increases  there is increasing stromal expression of  
CD10. 
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CONCLUSION 
To conclude, stromal CD10 expression in invasive ductal carcinoma 
of breast is directly correlated with higher tumor grade and HER2/neu 
positivity. It inversely correlates  with ER and PR expression. Expression of 
CD10 in stromal cells of breast cancer leads to inhibition of differentiation of 
stem cells, thus maintaining the stem cell population. This untargeted, 
unopposed stem cell population could lead to tumor recurrence even in 
patients treated with routine chemotherapy. 
Hence additional drugs like CPI0004Na, peptide prodrug of 
doxorubicin which cleaves CD10, could be added to therapy regimen in 
patients with stromal CD10 positivity. By adding new drugs targeting CD10, 
the stem cell population can be controlled and tumor recurrence and 
metastasis can be prevented. This helps in optimal individualized treatment 
option for each breast cancer patient. 
Further studies are needed by involving larger number of patients to 
assess the stromal CD10 expression, effect of chemotherapy on CD10 status 
and to develop new therapy targeting CD10. 
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ANNEXURES 
  
  
ANNEXURE -I 
MASTER    CHART 
S.NO: HPE NO: AGE HISTOPATHOLOGICAL GRADING ER PR HER2 CD10 
TUBULE NUCLEAR MITOSIS SCORE GRADE 
1 563/13 51 3 3 2 8 III 0 1 3 2 
2 706/13 51 3 3 2 8 III 0 0 0 2 
3 1802/13 42 3 2 3 8 III 1 0 3 2 
4 3/14 23 3 3 3 9 III 0 0 0 2 
5 3427/14 36 2 2 1 5 I 4 3 2 1 
6 1399/14 36 2 3 3 8 III 0 0 2 2 
7 4063/14 57 2 1 1 4 I 6 4 1 1 
8 670/14 60 2 3 3 8 III 1 0 1 2 
9 1252/14 35 2 2 2 6 II 1 1 0 0 
10 2279/14 41 2 2 1 5 I 0 5 3 1 
11 2039/14 40 2 1 1 4 I 0 0 3 2 
12 850/14 42 2 1 2 5 I 5 0 0 0 
13 2461/14 52 3 3 2 8 III 6 4 1 0 
14 82/15 42 3 3 2 8 III 0 1 3 2 
15 222/15 42 2 2 2 6 II 4 4 0 1 
16 2676/13 50 3 3 2 8 III 0 4 3 1 
17 794/15 50 2 2 2 6 II 1 3 0 0 
18 452/15 49 3 3 2 8 III 1 0 3 2 
19 1030/15 65 2 3 1 6 II 3 4 1 0 
20 2178/13 55 1 1 1 3 I 0 1 3 2 
21 1762/13 72 2 2 2 6 II 4 5 0 1 
22 2660/14 39 3 2 2 7 II 0 0 0 1 
23 1638/11 45 1 1 1 3 I 5 4 3 2 
24 637/11 40 1 2 1 4 I 5 1 2 0 
25 568/11 55 2 2 2 6 II 4 4 0 1 
26 380/11 65 3 3 2 8 III 4 3 2 0 
27 10/11 58 2 3 3 8 III 1 0 3 2 
28 1448/11 45 2 3 2 7 II 1 1 0 2 
29 612/11 50 3 3 2 8 III 0 0 3 2 
30 2727/13 55 2 2 2 6 II 4 5 2 0 
ANNEXURE II 
PROFORMA 
Name      age 
Ward      IP NO: 
Address 
Presenting complaints 
 Lump in breast 
 Pain 
 Discharge from nipple 
 Skin ulceration 
Duration of presenting illness 
Past history 
History of previous surgeries for breast lump 
History of chemotherapy/radiotherapy 
History of breast lump in other breast 
Family history 
Personal history 
 Diet 
 Menstrual history 
 Breast feeding history 
General examination 
Nourishment 
Built 
Conscious 
Febrile/afebrile 
Pallor 
Jaundice 
Cyanosis 
Clubbing 
Lymphadenopathy 
Edema  
Vitals  
 PR 
 RR 
 BP 
Local examination of the breast 
Side – right/left 
Quadrant 
Size of the tumor 
Fixity to the skin 
Fixity to the underlying fascia 
Examination of axillary lymph node 
 Number of node 
 Mobile/fixed 
 Size 
 Group of node:  anterior/posterior/lateral/apical 
Gross examination of modified radical mastectomy specimen: 
 Size of the specimen including skin, nipple, areola 
 Size of the tumor 
 Margins: infiltrative/circumscribed 
 Quadrant 
Histological diagnosis 
Any special type: 
Lymph node status – no: of positive nodes/no: of total nodes 
examined 
Histological grading 
 Tubule formation: 1/2/3 
 Nuclear pleomorphism:1/2/3 
 Mitosis:1/2/3Histological grade: I/II/III 
 
 
  
ANNEXURE - III 
ABBREVIATIONS 
AJCC American joint committee classification 
CD Cluster of Differentiation 
CEA Carcinoembryonicantigen 
CI Confidence Interval 
DAB Diaminobenzidine 
DCIS Ductal carcinoma in situ 
DPX Dextrene polystyrene xylene 
ER Estrogen receptor 
GCDFP Gross Cystic Disease Fluid Protein 
HER2 Human epidermal growth factor  receptor 
IARC International Agency for Research on Cancer 
LCIS Lobular carcinoma in situ 
NOS Not Otherwise Specified 
PR Progesterone receptor 
TBS Tris buffer solution 
WHO World health organization 
 
 
ANNEXURE - IV 
xg;g[jy; gotk ; 
 
bgah; : 
taJ  : 
ghypdk; : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; neha; Fwpapay; kUj;Jt 
Jiwapy; gl;l nkw;gog;g[ gapYk; khzth; kU.R.cyfehjd; mth;fs; 
nkw;bfhs;Sk; "khh;gf g[w;Wnehapy; CD10 tpd; btspg;ghl;oid mwpjy"; 
gw;wpa Ma;tpy; bra;Kiw kw;Wk; midj;J tpsf;f';fisa[k; nfl;Lf; 
bfhz;L vdJ re;njf';fis bjhpt[gLj;jpf; bfhz;nld; vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;idg; gw;wpa midj;J tptu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; 
Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; 
,e;j Ma;tpy; ,Ue;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;. 
 
,lk; :       ifbahg;gk; / nuif 
njjp : 
